Target Name: KRBOX4
NCBI ID: G55634
Review Report on KRBOX4 Target / Biomarker Content of Review Report on KRBOX4 Target / Biomarker
KRBOX4
Other Name(s): KRAB box domain containing 4 | KRBOX4 variant 1 | zinc finger protein 673 | Zinc finger protein 673 | Zinc finger family member 673 | Protein ZNF673 | Putative zinc finger transcription factor | KRAB box domain containing 4, transcript variant 1 | KRAB domain-containing protein 4 | ZNF673 | KRBX4_HUMAN | KRAB domain-containing protein 4 (isoform 1) | zinc finger family member 673 | putative zinc finger transcription factor | KRAB box domain-containing protein 4

Identifying KRBOX4: A Potential Drug Target and Biomarker

KRBOX4 is a protein that is expressed in various tissues of the body and has been identified as a potential drug target or biomarker. The protein is located in the KRAB box domain and is composed of 254 amino acids. In this article, we will discuss the potential implications of KRBOX4 as a drug target and its potential utility as a biomarker.

Potential Drug Target

KRBOX4 has been identified as a potential drug target due to its unique structure and location in the body. The KRAB box is a conserved region that is found in many proteins that play a role in intracellular signaling. The KRAB box is known for its ability to interact with various signaling molecules, including tyrosines, which are often involved in cell signaling pathways.

Research has shown that the KRAB box is also involved in the regulation of cell adhesion, which is a critical process that helps cells stick together and form tissues. This is important for the development and maintenance of tissues and organs, and is also involved in the development of cancer.

KRBOX4 has been shown to interact with several tyrosines, including the protein p53. p53 is a well-known tumor suppressor protein that is involved in the regulation of cell growth and division. KRBOX4 has been shown to physically interact with p53 and to regulate its activity.

This suggests that KRBOX4 may be a useful drug target for the treatment of diseases that are characterized by the over-expression of p53. Examples of such diseases include cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Biomarker

In addition to its potential as a drug target, KRBOX4 has also been identified as a potential biomarker for several diseases. The KRAB box is a conserved region that is found in many proteins that are involved in intracellular signaling, which makes it an attractive target for biomarkers.

Research has shown that KRBOX4 can be used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that KRBOX4 can be used as a biomarker for the detection of cancer, by measuring the expression of the protein in cancer cells.

In addition, KRBOX4 has also been shown to be involved in the regulation of cell adhesion, which is a critical process that helps cells stick together and form tissues. This makes KRBOX4 an attractive candidate for biomarkers that can be used to monitor the progression of diseases characterized by the disruption of cell adhesion.

Conclusion

In conclusion, KRBOX4 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and location in the body make it an attractive target for both drug development and biomarker research. Further research is needed to fully understand the potential implications of KRBOX4 as a drug target and biomarker.

Protein Name: KRAB Box Domain Containing 4

The "KRBOX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRBOX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

KRBOX5 | KRCC1 | KREMEN1 | KREMEN2 | KRI1 | KRIT1 | KRR1 | KRT1 | KRT10 | KRT10-AS1 | KRT12 | KRT126P | KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80